IFNA1 and systemic lupus erythematosus: The high prevalence of the IFN signature in SLE, particularly among clinical trial patients, supported the concept that identification of subgroups of patients with high IFN gene expression and targeting type I IFN could be an effective strategy for the treatment of SLE.